Drug intelligence / Profile preview

YZ-0121

Development stage: Preclinical
Lead developer: Guangdong Yinzhu Pharmaceutical Technology
Modality: Small Molecules
Administration: Oral

Overview

YZ-0121 is a preclinical **fixed-dose small-molecule combination** being developed by Guangdong Yinzhu Pharmaceutical Technology for **KRAS-positive non-small cell lung cancer**. The program is reported to target nuclear factor kappa B signaling and is listed in the developer's compound-formulation development platform; the individual active ingredients, formulation, route of administration, and precise pharmacologic effect on NF-κB have not been publicly disclosed.

Targets

NF-κB

Beyond the preview

Go deeper on YZ-0121.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YZ-0121.

Explore the full profile